#CreativeDisruption: The Future of #AI and NextGen Therapies

Want to hear what sector’s most influential thinkers say about where AI and next-gen therapies are heading in 2026?

AI is rapidly reshaping emerging biotech, advanced therapies and biologics in the UK. Machine learning now enables the analysis of large and complex datasets, supporting the discovery of new biomarkers and therapeutic targets and improving the modelling of biological responses. This leads to more precise and better targeted biologics and advanced therapies.

UK biotech organisations are also forming deeper partnerships with technology companies to access advanced data analytics and embed AI more effectively into research pipelines. Government backed initiatives are strengthening this progress and accelerating innovation.

AI driven drug repurposing is gaining momentum, helping redirect existing compounds to new indications, reducing development timelines and improving cost efficiency. With these advances accelerating, the UK remains strongly positioned to lead in biologics and advanced therapies both scientifically and commercially.

Chatham House Rules apply - "what goes on in the Forum, stays in the Forum - so to speak!"

Who Should Attend

The #CreativeDisruption Forum is designed for professionals working in life sciences who are driving innovation and growth. It is ideal for:

• Founders and executives of biotech
• R&D and clinical development leaders
• Investors and business strategists in the life sciences
• Innovation managers, consultants, and academic partners involved in commercialisation
• Students and early-career researchers interested in understanding how scientific innovation translates into successful business ventures

Schedule:

10.00 - 10.30 – Arrival and Networking

10.30 - 10.50 – Introductions from our Sponsors

10.50 - 11.25 – Keynote Session:

11.20-11.35 - Keynote Session:

11.35 - 12.10 – Keynote Session: Latest Trends in Biologics Companies

12.10-12.30 – Coffee Break & Networking

12.30 - 13.00 – Keynote Session: Strategies for Advanced Therapeutics Companies

13.00 - 13.30 – Keynote Session: Field Insights from Leading Companies

13.30 - 14.30 – Lunch Break and networking

14.30 - 15.15 – Workshops

15.15 - 15.45 – Workshop Group Leader Presentations

15.45 - 16.00 – Closing with Prof. Tony Sedgwick

16.00 - End

Heart of Life Science Innovation at #CreativeDisruption Forum

Each #CreativeDisruption Forum centres on open dialogue, expert insight and interactive discussions, guided by our resident thought leader, Prof. Tony Sedgwick.

Known as the www.ThoughtDisruptor.com, Tony brings extensive experience as a trained pathologist, former Global Head of Clinical Research at Roche AG, and CEO and Chairman across several life science companies. He also draws on his background in psychology and leadership to help participants look at familiar challenges from new angles.

Participants can expect:

•⁠ ⁠Exchange ideas with peers facing similar strategic and operational issues,

•⁠ ⁠Gain practical insights from experienced founders and executives,

•⁠ ⁠Explore actionable approaches to commercialisation and growth,

•⁠ ⁠Strengthen their professional networks across the UK life sciences community.

The Forum provides a trusted environment to discuss challenges openly, share lessons learned, and explore new ways of driving innovation.

We promise that our #CreativeDisruption Forum will be like no other life sciences event or business network you have experienced. You will be walking out of the session inspired, educated and more connected.

ADMISSION FEE for Service Companies such as CROs, CDMOs, Law Firms and Patent Attorneys, Consultancy Firms = £120 - ALL-INCLUSIVE

ADMISSION FEE for Innovative Emerging Life Science Companies and Independent Consultants = £60

Investors can apply for free entry by writing to graham@biosell.co.uk.

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface. CDD helps scientists register entities, track inventory, manage assay data, capture experiments, calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. CDD was founded in 2004 and presently serves thousands of researchers doing drug discovery all around the world. Learn more at www.collaborativedrug.com